text:
Electric motorcycles and scooters, as the type name implies, run on electricity. Obviously, the two wheelers don't have a very long extension lead plugged into a socket, but instead they run on batteries.
But normal 12V motorcycle batteries as we know them will not supply enough power to propel the bike any further than a mile or two. No, to be able to ride a reasonable distance on an electrically powered two wheeler, you need more batteries, and these batteries need to have a higher energy.
Take for example one of the top American electric motorcycle manufacturers, Brammo. This is what a Brammo will look like if you cut it open:
Those blue things are the batteries. They are Lithium-Ion batteries, and they are not 12V but 103 Volt (with a max voltage of 117.6V). They supply a total capacity of 9.31 kWh, with a peak of 10.2 kWh.
It's the battery pack capacity that counts for electric motorcycles. The higher the number, the more power it has.
But to recharge so many batteries requires special equipment. Depending on where you plug your bike in (known as Level 1, 2 or even 3 charging) you can fully charge your bike in 3.5 hours or 8 hours (in the case of level 1, your household electrical socket).
But all those batteries make the bike heavy. If you look closely at the photos, you'll see that the engine is the smallest part, in sharp contrast with its ICE (Internal Combustion Engine) cousins. The biggest volume is taken up by the batteries. In total, the Brammo Empulse weighs 460 lbs (some 213 kilos).
But despite the heavy weight, the Brammo can still deliver an incredible 90 Nm of peak torque, more than most sportsmotorcycles.
Even electric scooters use similar large amounts of batteries. Take for example the BMW C-Evolution:
Apart from the 12 cells (which by the way come from the electric car from BMW, the i3), there is one "normal" 12V battery located in the front housing which takes care of the normal electrical functions (dashboard, horn, etc).
The engine's batteries, like the Brammo, are Lithium-Ion and supply 8 kWh. Recharging these batteries using a standard domestic 12A socket takes 4 hours (if it's a 16A socket, it'll take 3 hours).
The 12 cells supply 60 Ah and 133V, and the whole scooter weighs 265 kilos. But despite that weight, you get a torque of 72 Nm which is available all the time.
So as you can see, batteries take up the biggest amount of space on an electric bike. By far! Over the next few years, even decade, the batteries will start becoming smaller, lighter and packing more punch, allowing for longer rides. But until then, you will need to content yourself with riding 60 to 100 miles before requiring a charge. Far enough for a daily commute, not far enough for a weekend ride of the Tail of the Dragon at Deals Gap.


text:
The Vancouver Sun's book club is discussing The Confabulist by Vancouver author Steven Galloway. It's a historical novel about the life, loves and murder of Henry Houdini. We will be chatting online with Galloway at noon on Wednesday, May 28. Plan to join the conversation at www.vancouversun.com/books.
Julia Denholm: What I like about Houdini most in this book is his humanness: he starts out as a struggling vaudevillian, dumps his brother, terrifies and repeatedly betrays his wife, is nasty, is flawed. Becomes very famous. Stays nasty. Stays flawed.
Today we are far removed from the cult of fame that permitted "celebrities" a certain mystique: now we know everything about those nasty, flawed celebrities.
But Houdini, for the most part, is remembered for his persona, despite the many books written about the man. Galloway introduces us to the man. Whether he's a real man or an invention is the question.
Monique Sherrett: The famous and infamous are always fascinating, especially entertainers. Frank Sinatra, for example, is so lauded but also many say Ol' Blue Eyes wasn't a nice guy. These men at the top of their game need such an ego to perform, I'm sure that if they don't start out nasty, as Julia says, they develop that as a coping mechanism. What I like about Galloway's version of Houdini is that he gives us the entertainer and a version of the man behind the scenes. Both are inventions. Houdini invented himself: the name, the act, everything. And that's the great American promise, that you can come from nothing and build your fortune. What a perfect illusion.
Speaking of invention and illusions, there's something uncanny about Houdini. His life is a lovely dichotomy. He spent 26 years in the 19th century with horse and buggy, telegrams and struggling to make a name for himself and then 26 years in the 20th century with automobiles, telephones, radio and riches and celebrity.
The technological advances alone must have seemed like magic to people. Then for a magician as practised in slight of hand and flexibility as Houdini to use that technology in his act, it must have been a double whammy for the audience.
Ian Weir: In one very real sense, Galloway's Houdini is the 20th century's first superhero. He's Batman before comic books existed, and I love the way the novel plays on that archetype. Like all great superheroes, he's the projection of our adolescent yearnings — which is, I think, a big part of the reason that we stay so invested in the character, despite (as Julia notes) his pretty major moral transgressions.
This resonates on another level with the wonderful Robert-Houdin quote that Martin Strauss cites early in the novel: "A magician is an actor playing a magician." There's something in this that goes right to the very heart of post-modern bewilderment — our desperate sense that we need to inhabit a self-created persona to exist in the first place.
Melanie Jackson: I enjoyed how Houdini reveals the practical how-to's to supposed magic tricks. There's a scene set in 1918 where he instructs some American soldiers and sailors on how to escape a sinking ship. "People drown … because they lose their sense of direction. If you become disoriented you're done for. Watch the air bubbles. They're your best clue to which way is up." He also tells them how to escape being bound tightly with ropes. In other words, nothing is impossible if you just think it through. It's a reassuring perspective.
Houdini is the anti-fabulist. He reminds me of Sherlock Holmes, who similarly explains seemingly unsolvable mysteries. No wonder Houdini gets so upset with Holmes's creator, Sir Arthur Conan Doyle, for believing in ectoplasm (yech!), etc. Doyle is betraying his own protagonist with such nonsense. Houdini as superhero? He's Holmesian, so yes, I agree.
Daphne Wood: A superhero indeed — with all the mystery and dark secrets that go along with it! The title of the novel was intriguing to me — when I learned "confabulation" is basically an innocent account based on false memories, without malice or deliberate attempts to deceive, I was even more intrigued. Could I really depend on the perspective of the narrator — or did his illness already progress to the point that true memories were replaced with fabrications? Critical scenes where the two main characters intersect were described by the unreliable witness, Martin Strauss, and leave so much in question. Is the reader being tricked? Or are we receiving an explanation for the illusion? These mysteries kept my attention focused on Houdini, watching to see if there were any subtle 'reveals' about his true nature or whether he would continue to show only what the audience (or reader) wanted to believe. A fascinating literary technique to depict the world's greatest illusionist.
Our book club panel includes Ian Weir, author of the novel Daniel O'Thunder; Vancouver young-adult author Melanie Jackson; Daphne Wood, the Vancouver Public Library's director, planning and development; Julia Denholm, Dean, Arts & Sciences, Capilano University; Monique Sherrett, principal at Boxcar Marketing and founder of somisguided. com; Trevor Battye, a partner in Clevers Media; Vancouver Sun books editor Tracy Sherlock; and city editor Bev Wake.

subset: commoncrawl


text:
AIDS 'cures': Snake oil or salvation?
December 1997
A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
Log on to the Internet, call up a search engine and type in AIDS+cure. Or pick up some alternative newspapers or magazines.
A few clicks of your mouse or a close reading of an occasional advertisement directs you to companies making claims like:
Are these claims for snake oil or salvation? Are there "natural" agents or devices which are non-toxic alternatives to conventional antiviral therapy for HIV disease?
The California AIDS Fraud Task Force (CAFTF), established in 1985 as the nation's first AIDS fraud task force, helps answer those questions.
Mission to empower, reduce risk
CAFTF is a voluntary, collaborative, statewide network of diverse individuals from the HIV community and representatives of community-based organizations and government agencies. The task force has a dual mission: to empower people with HIV to act on their own behalf in matters of health care, and to reduce the risk of harm caused by the lack of adequate, accurate information, and by misinformation.
"HIV/AIDS health fraud is any false, misleading or unproven claim about the prevention, treatment or cure of HIV/AIDS," says Marcy Fenton, M.S., R.D., CAFTF member and AIDS Project Los Angeles' nutrition advocate.
HIV/AIDS health fraud is dangerous for several reasons. "Just because a product is advertised on-line or in a newspaper doesn't mean its safety and efficacy has been tested adequately," says Fenton. "Some products are dangerous, sometimes nothing more than household cleaners mixed together."
Expense can be another factor. "Fraudulent products don't work," says Fenton. "They're not covered by insurance and simply are a waste of money."
Not all are fraudulent
Not all therapies complementing drugs that are approved by the Food and Drug Administration are fraudulent.
"Many products and treatments used by people with HIV aren't regulated by the FDA and are important complements to licensed drugs," says Ruben Gamundi, program manager of APLA's Client Health Education and Advocacy Unit. "Herbs, acupuncture and elements of traditional Chinese medicine are important components of anti-HIV therapy for many people. People with HIV should always discuss all the therapies they use with all of their health care providers."
Products or treatments with suspicious claims should be investigated thoroughly, Gamundi warns.
FDA approval required
According to federal law, a manufacturer cannot make therapeutic claims about a product without Food and Drug Administration (FDA) approval.
Products or treatments may be regulated by the FDA or state authorities, depending on where they are produced or made available, among other factors. While CAFTF does not assess the efficacy of a product or treatment, it does act as an information loop, giving consumers information about questionable products and alerting regulatory agencies to the advent of new, potentially fraudulent products.
"AIDS fraud is false advertising. We're here to help educate consumers," says Trisha Johnson, task force chair. Consumers who call the information line number, (800) 459-4503, with questions about a product are given any available information about it. "We also steer callers back to their health-care provider and other avenues of information like the product's manufacturer, AIDS-service organizations, pharmacists, nutritionists and health educators to get objective feedback," says CAFTF member Rosario Vior.
The task force also monitors trends in the availability and nature of potentially fraudulent products and treatments. "Information gleaned from task force members with close ties to the community and from calls to the information line is shared with other members and with the task forces of other states," says task force member Ed Whitford. "This assists local communities, states and FDA health fraud coordinators identify trends."
This information can also lead the appropriate regulatory agency to investigate a product or treatment and its claims.
Some cases prosecuted
What's the appeal of products that seem too good to be true? "The hopelessness that some people living with HIV can have," says San Diego task force member John Rasmussen. For example, the manufacturers of Immunostim, a bathtub brew of household cleaners used as an IV treatment for cancer and AIDS, were convicted of fraudulent claims because of consumer and care-giver complaints.
The effects of successful, aggressive combination therapy on AIDS fraud are not completely clear. "There's been a change from the days when there was no hope for an effective therapy or cure for HIV to the position where people see some benefits in therapy," says Whitford. "We're not seeing as many far-out schemes. It's more difficult for promoters to make headway with their claims when there are more efficacious treatments available."
Some are especially vulnerable
Distrust of government in some communities can predispose them to the claims of fraudulent schemes. Economically challenged individuals who don't have access to FDA-approved drugs may be able to afford treatments that promise equally successful results at a fraction of the cost. Some members worry that recent news that HIV can't be eradicated after several years of treatment may increase AIDS fraud.
"Some dietary supplements don't make the claim they'll cure AIDS but promise to embellish health status or boost the immune system," Whitford warns. "They may do this with no proof. Or, they may boost the immune system and promote activated immune cells to increase HIV production."
"Californians love products described as 'natural,' 'organic' or 'herbal.' People think if it's natural it can't hurt me. Sometimes it isn't clear what dosage is correct or what the long-term effects might be."
'Safe place'
According to Rosario, health fraud transcends economic and social status.
"Fraud victims can be very embarrassed and reluctant to discuss their experiences," she says. "CAFTF exists as a safe place where people can tell their story. We hope that people who have suffered a loss of health or financial resources because of fraud will share their experiences with us so that others can learn from them."
If you encounter suspicious products or treatments for HIV or AIDS, contact the California AIDS Fraud Task Force for an opinion. You may protect your health and your pocketbook.
The California AIDS Hotline: (800) 367-2437) provides similar assistance in English, Spanish and Tagalog.
A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.


text:
- Your quote is empty!
- Get Lit with Outdoor LED Lighting
- Get Lit with Indoor LED Lighting
- Wiring Devices
- Get Lit with Indoor LED Lighting
Our 05-BRKLCSLED retrofit strip lights are designed to transform existing fluorescent strips into high performance LED luminaires. The 05-BRKLCSLED series is designed to deliver general ambient lighting in a variety of indoor settings, including schools, offices, hospitals and stores. This high-efficacy luminaire provides long-life and uniform illumination, as well as standard 0-10vdc dimming capability.
▪ Available in 3500k (warm/neutral white), 4000k (neutral white) and 5000k (cool white) color temperatures.*
▪ Long-life LEDs provide 122,000 hours of operation with at least 70% of initial lumen output (L70).**
▪ 05-BRKLCSLED4FT provides 2,833 luminaire lumens (123 lumens per watt, LPW) at 3500k; 2,990 luminaire lumens
(130 LPW) at 4000k; and 3,013 luminaire lumens (131 LPW) at 5000k.*
▪ 05-BRKLCSLED8FT provides 5,842 luminaire lumens (127 lumens per watt, LPW) at 3500k; 5,980 luminaire lumens
(130 LPW) at 4000k; and 6,026 luminaire lumens (131 LPW) at 5000k.*
▪ Uniform illumination with no visible LED pixelation.
▪ Universal 120-277 AC voltage (50-60Hz) is standard.
▪ 0-10vdc dimming capability is standard.
▪ Power factor > 0.90.
▪ Total harmonic distortion < 20%.
▪ Color rendering index > 80.
▪ Steel housing and acrylic lens.
▪ Easy installation in existing fluorescent strip housings
* Contact factory for other color temperatures and lumen packages.
** L70 hours are IES TM-21-11 calculated hours.
▪ cULus approved for damp locations (-20 °C to 50 °C / -4 °F to 122 °F).
▪ DLC premium approved.
▪ Complies with FCC Part 15, Class A.
▪ Complies with IEEE C.62.41-1991, Class A input transient surge protection (2.5kV).
▪ Complies with IEC 61000-4-2 level 2 (4kV) electrostatic discharge (ESD).
▪ Complies with RoHS (Restriction on Hazardous Substances) requirements.
▪ 5-year warranty of all electronics and housing.
Retrofit 4 FT LED Covered Strip Light - 23W - Up to 3,013 Lumens - DLC Premium - UL Listed - Dimmable - 35K/4K/5K - 120-277VRETROFIT 8 FT LED COVERED STRIP LIGHT - 46W ...
Customer Service
Cost Less Lighting © 2018


text:
Journal of The History of the Behavioral Sciences
Journal of The History of the Behavioral Sciences
Vol 53(4 Issues in 2017 )
Print ISSN: 0022-5061
Online ISSN: 1520-6696
Impact Factor: .667
Digital version available through Wiley Online Library
The Journal of the History of the Behavioral Sciences is a quarterly, peer-reviewed, international journal devoted to the scientific, technical, institutional, and cultural history of the social and behavioral sciences. The journal publishes research articles, book reviews, and news and notes that cover the development of the core disciplines of psychology, anthropology, sociology, psychiatry and psychoanalysis, economics, linguistics, communications, political science, and the neurosciences. The journal also welcomes papers and book reviews in related fields, particularly the history of science and medicine, historical theory, and historiography.


text:
NBC's Dracula Casts Its Van Helsing
Thomas Kretschmann.
NBC's Dracula, set to star Jonathan Rhys Meyers as the Count, has cast Thomas Kretschmann as Van Helsing. The German-born Kretschmann has appeared in King Kong and The River, as well as playing Dracula in Dario Argento's 2012 adaptation. The new series is set in the 1890s, with Dracula masking as an American businessman in London. Van Helsing is "a brilliant professor with a cool exterior who is obsessed with revenge," which "makes him more of a threat to the public than to Dracula."


text:
Hey all, passing this on from a friend. I hope it's of interest and a good opportunity for some of you:
Announcing: The Siemens Foundation Empowering People Award
The Empowering People Award is looking for solutions or products which have the potential of social impact for people in developing and emerging countries in the following categories:
- Water & Waste Water
- Energy
- Food & Agriculture
- Waste Management & Recycling
- Healthcare
- Housing & Construction
- Information & Communication Technology
The prizes will be allocated as follows:
1st Prize EUR 50,000.00
2nd Prize EUR 30,000.00
3rd Prize EUR 20,000.00
20 runners up EUR 5,000.00 (each)
Please have a look at the criteria here: http://www.empowering-people-award.siemens-stiftung.org/empowering-people-award/evaluation-criteria/ . This is a great opportunity to receive recognition and funding and I hope you will apply and spread the word about this.
To register: http://www.empowering-people-award.siemens-stiftung.org/award-registration/
Feel free to spread the word on social media channels, and find the Empowering People Award on Twitter: @emp_ppl_award
And if you have any questions or need any more info, you can follow up with Vallabh Rao (@raovallabh).
Good luck!


text:
Samsung will offer extended battery life to mobile phones through their highly integrated application processors incorporating the Advanced Power Controller
SANTA CLARA, CALIF., AND CAMBRIDGE, UK – June 21, 2006 – National Semiconductor Corp. [NYSE:NSM] and ARM [(LSE:ARM); (Nasdaq:ARMHY)] today announced that Samsung [KSE:005930] has become the first ARM® Partner to publicly announce its license of the National Semiconductor PowerWise® technology, specifically the Advanced Power Controller (APC™). This technology will enable Samsung to offer customers faster, feature-rich mobile phone applications, incorporating "intelligent" power control for increased battery efficiency.
National Semiconductor's PowerWise technology features a synthesizable AMBA® methodology-compliant macrocell called the APC, which includes a hardware performance monitor. This combination allows the APC block to automatically compensate and minimize the voltage supply based upon real-time, on-chip system conditions. This results in reduced system power and energy consumption for extended battery life. APC technology, in conjunction with a dynamic voltage and frequency scaling SoC and ARM Intelligent Energy Manager (IEM™) Software, can further reduce power and energy consumption demands upon the battery by as much as 25 percent to 30 percent.
The APC communicates to an external Power Management Unit (PMU) through the open-standard PWI interface® (PWI) (www.pwistandard.org). The PMU then delivers the lowest level of required voltage to the SoC, minimizing active and static system power and energy consumption.
"Today's leading portable device manufacturers need to ensure that consumers are able to enjoy high-data rate features and extended battery life," said Ravi Ambatipudi, director of advanced power management products, National Semiconductor. "By combining PowerWise technology and PWI, Samsung will be able to deliver the benefits of extremely power and energy-efficient SoC semiconductor integrated circuits to the mobile phone market."
The APC forms an integral part of the ARM IEM technology, which includes ARM Artisan® Physical IP, AMBA 3 AXI™ interconnect, IEM software and IEC hardware.
"The collaboration between ARM and National Semiconductor is designed to bring technologies to market that deliver increased power and energy efficiency to mobile and wireless devices," said Kevin McIntyre, IEM product manager, ARM. "The continuing collaboration between ARM and National Semiconductor will help realize the full performance potential of advanced mobile phones, enabling these rich new applications."
National Semiconductor's AMBA technology-compliant PowerWise technology, APC, is available for licensing through ARM or National Semiconductor for use with any ARM processor. The ARM IEM technology is available today from ARM. There are currently three IEM technology-enabled processors: the ARM1176JF-S™ processor, the ARM1176JZF-S™ processor, and the ARM11™ MPCore™ multiprocessor. The technology is also available in the Cortex™ family of processors.
About ARM
ARM designs the technology that lies at the heart of advanced digital products, from mobile, home and enterprise solutions to embedded and emerging applications. ARM's comprehensive product offering includes 16/32-bit RISC microprocessors, data engines, 3D processors, digital libraries, embedded memories, peripherals, software and development tools, as well as analog functions and high-speed connectivity products. Combined with the company's broad Partner community, they provide a total system solution that offers a fast, reliable path to market for leading electronics companies. More information on ARM is available at http://www.arm.com.
About National Semiconductor
National Semiconductor, the industry's premier analog company, creates high-value analog devices and subsystems. National's leading-edge products include power management circuits, display drivers, audio and operational amplifiers, interface products and data conversion solutions. National's key analog markets include wireless handsets, displays and a variety of broad electronics markets, including medical, automotive, industrial, and test and measurement applications. Headquartered in Santa Clara, Calif., National reported sales of $2.16 billion for fiscal 2006, which ended May 28, 2006. Additional company and product information is available at www.national.com.
ARM and AMBA are registered trademarks of ARM Limited. ARM11, ARM1176JF-S, ARM1176JZF-S, IEM, IEC, AXI, APC, Cortex and MPCore are trademarks of ARM Limited. Artisan and Artisan Components are trademarks of ARM Physical IP, Inc. "ARM" is used to represent ARM Holdings plc; its operating company ARM Limited; and the regional subsidiaries ARM INC.; ARM KK; ARM Korea Ltd.; ARM Taiwan; ARM France SAS; ARM Consulting (Shanghai) Co. Ltd.; ARM Belgium N.V.; AXYS Design Automation Inc.; AXYS GmbH; ARM Embedded Solutions Pvt. Ltd.; and ARM Physical IP, Inc.
National Semiconductor, PowerWise and PWI interface are registered trademarks of National Semiconductor Corporation. All other brands or product names are the property of their respective holders.
Contact Details:
|Niall O'Malley
Text 100
+44 208 846 0740
|Michelle Spencer
+44 1628 427780


text:
Welcome to Travellers Oasis Backpackers in Cairns. More Info »
HOME AWAY FROM HOME. Non party resort style. Great nights sleep. Quiet and clean set up for the experience... More Info »
Home Sweet Home... Tropic Days is a charming little guest house set in tropical landscaped gardens and a relaxed... More Info »
We've got free air conditioning, even on discounted rooms; plus there's free storage for your luggage. More Info »
Dreamtime Travellers Rest is a small, relaxed and homely independent hostel. Winning Best hostel Australia in 2008... More Info »
Nomads Cairns Backpackers Resort is the ultimate tropical backpackers hostel located just minutes from major... More Info »
Gilligan's Backpackers Hotel & Resort is the ultimate experience in accommodation and entertainment in the heart of... More Info »
The Northern Greenhouse is a resort style hostel, centrally located in the heart of Cairns and is only a short walk... More Info »
Global Backpackers Central is located in the heart of Cairns CBD. Surrounded by shops, restaurants & all the most... More Info »
Enjoy FREE, fast WiFi, a tropical swimming pool, free pool table, cinema room with Netflix and fully equipped... More Info »
Corona Backpackers is situated in the heart of Cairns city, close to all amenities and attractions. We are 2 minutes... More Info »
Meet real people that enjoy traveling and having fun. Here all things are considered, is also the cheapest because... More Info »
Geckos Backpackers is a Magnificent Historical, Heritage Place set amongst lush beautiful gardens. The buildings... More Info »
The * ULTIMATE LOCATION * on the Cairns Waterfront and Esplanade.... Stay where the action is in a clean, quiet,... More Info »
Mad Monkey Cairns offers affordable upmarket hostel accommodation right in the centre of Cairns City. We are often... More Info »
The look and feel of a beach house in an unbeatable location, you will instantly feel relaxed and at home. We are a... More Info »
People come back, again and again or have heard of us through their friends. We're run by friendly, helpful and... More Info »
Hides Hotel Cairns offers affordable accommodation right in the heart of Cairns. It is surrounded by restaurants,... More Info »
With our quiet and convenient location and our friendly and knowledgeable staff, we hope to make your time in Cairns... More Info »
Golden Sands Resort Cairns is right on the Yorkeys Knob beachfront with only open lawns and gardens separating your... More Info »
Video guides, travel podcasts, city maps & free city guides. What to eat, where to stay and things to do and see - our travel guides have it all.Find a guide »
We want to make sure that you get to explore as much of Paris as possible and that includes the nightlife scene. We've compiled some of the best places in Paris to check out if ...Read more »
We offer the most comprehensive selection of hostels on the internet with over 33,000 great places to stay in 170 countries. The ultimate online resource for hostels everywhere.Find great value hostels »


text:
How to Choose the Best Layout for Your Garden
There's no question that developing and planning for a garden consists of a long list of details and needed tasks. However, before the first seeds are planted, make sure selecting a garden layout is at the top of your list. Your garden layout and design play an important role in the success of your garden, affecting how well plants will grow based on these tips.
1. Time Management: Consider the overall size of your yard when selecting how big or small you want your garden. Also, make sure you have the proper quantity of plants and the amount of time to attain to your garden needs. If you're unsure what you're capable of maintaining, start small - you can always make additions.
2. Location: Select an area in your yard that receives direct sunlight and is level. When choosing a location and layout for your garden, avoid placing it next to tall structures or buildings that may block sunlight from reaching your plants or at the bottom of a hill or slope, which may drain excess water into your garden. If you have future plans of expanding your garden, make sure you choose a location and design that will allow you to do so.
3. Space: It's important to have knowledge about your plants to help you determine how much space they'll need to grow and where to place them in your garden. Some plants, like tomatoes, need to be staked and require plenty of room to grow where others, such as herbs, don't need as much space. Knowing about plant needs and maintenance will not only help you choose a suitable garden layout, it will also help you create an environment where your plants can thrive.
The Dirt from Troy-Bilt®, March/April 2014


text:
SOURCE: Onyx Pharmaceuticals, Inc.
January 07, 2013 12:45 ET
Kyprolis™ (carfilzomib) for Injection Net Sales Exceed $62 Million for 2012
Kyprolis™ (carfilzomib) for Injection Net Sales Exceed $62 Million for 2012
SOUTH SAN FRANCISCO, CA--(Marketwire - Jan 7, 2013) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reviewed 2012 accomplishments and announced several 2013 business updates, which the company discussed during its presentation at the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2013 at 9:30 a.m. Pacific Time.
"In 2012, we executed successful launches for Kyprolis™ (carfilzomib) for Injection and Stivarga® (regorafenib) tablets, a Bayer compound, transforming Onyx from a single-product company into a company with three approved therapies for patients with some of the most difficult-to-treat cancers," said N. Anthony Coles M.D., Chairman and Chief Executive Officer of Onyx. "Since the launch of Kyprolis in late July of last year, we have seen strong initial adoption trends and rapid account penetration, with net sales exceeding $62 million in 2012. We continue to strategically invest in the development of Kyprolis to unlock additional value across all lines of therapy. We look forward to continuing our business momentum in 2013, with many near-term clinical, regulatory, and commercial milestones across the proteasome and kinase inhibitor franchises."
2012 Achievements and 2013 Milestones
Kyprolis™ (carfilzomib) for Injection
Stivarga® (regorafenib) tablets
Stivarga is a Bayer compound developed by Bayer and jointly promoted by Bayer and Onyx in the U.S. In 2011, Bayer entered into an agreement with Onyx, under which Onyx receives a royalty on all global net sales of Stivarga in oncology.
Nexavar® (sorafenib) tablets
Nexavar is co-developed by Onyx and Bayer, except in Japan where Bayer manages all development. The companies co-promote Nexavar in the U.S. Outside of the U.S. Bayer has exclusive marketing rights, and Bayer and Onyx share profits globally, excluding Japan.
Live Webcast
Interested parties may access a webcast of the presentation on our website at:
A replay will be available within 24 hours of the completion of the presentation through January 21, 2013.
Important Indication and Safety Information for Kyprolis™ (carfilzomib) for Injection
On July 20, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Kyprolis™ (carfilzomib) for Injection for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval was based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. There were 37 deaths in the Phase 2 studies, or 7% of patients. The most common causes of death, other than disease progression, were cardiac (5 patients), end-organ failure (4 patients), and infection (4 patients). Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia; pulmonary hypertension, pulmonary complications, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.
Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months, and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications.
Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients. Dyspnea was reported in 35% of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade 5) was reported.
Infusion reactions, characterized by a spectrum of systemic symptoms including fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina can occur immediately following or up to 24 hours after administration of Kyprolis. Administration of dexamethasone prior to Kyprolis reduces the incidence and severity of reactions. Tumor lysis syndrome (TLS) occurred following Kyprolis administration in < 1% of patients. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS.
Thrombocytopenia following Kyprolis administration resulted in a dose reduction in 1% of patients and discontinuation of treatment with Kyprolis in < 1% of patients.
Cases of hepatic failure, including fatal cases, have been reported (< 1%). Kyprolis can cause elevations of serum transaminases and bilirubin.
There are no adequate and well-controlled studies in pregnant women using Kyprolis. Females of reproductive potential should be advised to avoid becoming pregnant while being treated with Kyprolis. The most common serious adverse reactions were pneumonia, acute renal failure, pyrexia, and congestive heart failure. The most common adverse reactions (incidence of 30% or greater) observed in clinical trials of patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. Serious adverse reactions were reported in 45% of patients.
Full prescribing information is available at http://www.kyprolis.com.
About Stivarga® (regorafenib) Tablets
Stivarga is approved in the U.S. for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.
Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.
In in vitro assays, Stivarga or its major metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E,SAPK2, PTK5, and Abl at concentrations of Stivarga that have been achieved clinically.
In in vivo models, Stivarga demonstrated anti-angiogenic activity in a rat tumor model, and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for human colorectal carcinoma.
Important Safety Information for Stivarga (regorafenib) Tablets
Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.
Hepatotoxicity: Severe drug-induced liver injury with fatal outcome occurred in 0.3% of 1100 STIVARGA-treated patients across all clinical trials. Liver biopsy results, when available, showed hepatocyte necrosis with lymphocyte infiltration. In Study 1, fatal hepatic failure occurred in 1.6% of patients in the STIVARGA arm and 0.4% of patients in the placebo arm; all the patients with hepatic failure had metastatic disease in the liver.
Liver Function Monitoring: Obtain liver function tests (ALT, AST, and bilirubin) before initiation of STIVARGA and monitor at least every 2 weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the upper limit of normal (ULN) or baseline values. Temporarily hold and then reduce or permanently discontinue STIVARGA, depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis.
Hemorrhage: STIVARGA caused an increased incidence of hemorrhage. The overall incidence (grades 1-5) was 21% in STIVARGA-treated patients compared to 8% in placebo-treated patients in Study 1. Fatal hemorrhage occurred in 4 of 500 (0.8%) STIVARGA-treated patients and involved the respiratory, gastrointestinal, or genitourinary tracts. Permanently discontinue STIVARGA in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.
Dermatological Toxicity: STIVARGA caused an increased incidence of hand-foot skin reaction (HFSR) (also known as palmar-plantar erythrodysesthesia [PPE]) and rash, frequently requiring dose modification. The overall incidence of HFSR (45% vs 7%) and the incidence of grade 3 HFSR (17% vs 0) were increased in STIVARGA-treated patients compared to placebo-treated patients in Study 1. The overall incidence of rash (26% vs 4%) and the incidence of grade 3 rash (6% vs < 1%) were higher in STIVARGA-treated patients in Study 1. Temporarily hold and then reduce or permanently discontinue STIVARGA, depending on the severity and persistence of dermatologic toxicity.
Hypertension: STIVARGA caused an increased incidence of hypertension (30% of STIVARGA-treated patients vs 8% of placebo-treated patients in Study 1). Hypertensive crisis occurred in 0.18% of 1100 STIVARGA-treated patients across all clinical trials. Do not initiate STIVARGA until blood pressure is adequately controlled. Monitor blood pressure weekly for the first 6 weeks of treatment and then every cycle, or more frequently, as clinically indicated. Temporarily or permanently withhold STIVARGA for severe or uncontrolled hypertension.
Cardiac Ischemia and Infarction: STIVARGA increased the incidence of myocardial ischemia and infarction (1.2% for STIVARGA-treated patients vs 0.4% of placebo-treated patients). Withhold STIVARGA in patients who develop new or acute cardiac ischemia or infarction, and resume only after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS occurred in 1 of 1100 STIVARGA-treated patients across all clinical trials. Confirm the diagnosis of RPLS with MRI and discontinue STIVARGA in patients who develop RPLS.
Gastrointestinal Perforation or Fistula: Gastrointestinal perforation or fistula occurred in 0.6% of 1100 patients treated with STIVARGA across clinical trials. Permanently discontinue STIVARGA in patients who develop gastrointestinal perforation or fistula.
Wound Healing Complications: Treatment with STIVARGA should be stopped at least 2 weeks prior to scheduled surgery. The decision to resume STIVARGA after surgery should be based on clinical judgment of adequate wound healing. STIVARGA should be discontinued in patients with wound dehiscence.
Embryo-Fetal Toxicity: STIVARGA can cause fetal harm when administered to a pregnant woman. Use effective contraception during treatment and up to 2 months after completion of therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Nursing Mothers: Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from STIVARGA, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Most Frequently Observed Adverse Drug Reactions in Metastatic Colorectal Cancer (mCRC) (≥30%): The most frequently observed adverse drug reactions (≥30%) in STIVARGA-treated patients vs placebo-treated patients in mCRC, respectively, were: asthenia/fatigue (64% vs 46%), decreased appetite and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs 17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31% vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%).
For full prescribing information, including BOXED WARNINGS, visit www.stivarga-us.com.
About Nexavar® (sorafenib) Tablets
Nexavar is approved in the U.S. for the treatment of patients with unresectable hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma. Nexavar is thought to inhibit both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is currently approved in more than 100 countries.
Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of cancers.
Important Safety Information for Nexavar (sorafenib)
Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.
Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.
An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar.
Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, if required.
Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Nexavar should be discontinued if Stevens-Johnson Syndrome or toxic epidermal necrolysis are suspected as these may be life threatening.
Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar. Discontinue Nexavar in the event of a gastrointestinal perforation.
Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time (PT), International Normalized Ratio (INR) or clinical bleeding episodes.
Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.
Nexavar in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. The safety and effectiveness of Nexavar has not been established in patients with non-small cell lung cancer.
Nexavar can prolong the QT/QTc interval and increase the risk for ventricular arrhythmias. Avoid use in patients with congenital long QT syndrome and monitor patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.
Drug-induced hepatitis with Nexavar may result in hepatic failure and death. Liver function tests should be monitored regularly and in cases of increased transaminases without alternative explanation Nexavar should be discontinued.
Nexavar may cause fetal harm when administered to a pregnant woman. Women of child-bearing potential should be advised to avoid becoming pregnant while on Nexavar and female patients should also be advised against breastfeeding while receiving Nexavar.
Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar.
Avoid concomitant use of strong CYP3A4 inducers, when possible, because inducers can decrease the systemic exposure of sorafenib. Nexavar exposure decreases when co-administered with oral neomycin. Effects of other antibiotics on Nexavar pharmacokinetics have not been studied.
Most common adverse reactions reported for Nexavar-treated patients vs. placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs. 25%), fatigue (46% vs. 45%), abdominal pain (31% vs. 26%), weight loss (30% vs. 10%), anorexia (29% vs. 18%), nausea (24% vs. 20%), and hand-foot skin reaction (21% vs. 3%). Grade 3/4 adverse reactions were 45% vs. 32%.
Most common adverse reactions reported for Nexavar-treated patients vs. placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs. 13%), rash/desquamation (40% vs. 16%), fatigue (37% vs. 28%), hand-foot skin reaction (30% vs. 7%), alopecia (27% vs. 3%), and nausea (23% vs. 19%). Grade 3/4 adverse reactions were 38% vs. 28%.
During post approval use of Nexavar, the following adverse drug reactions have been identified: angioedema and drug-induced hepatitis, including reports of hepatic failure and death.
For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.
Forward-Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Kyprolis (carfilzomib), Nexavar (sorafenib), Stivarga (regorafenib), oprozomib, or PD-0332991. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Note Regarding DECISION Results
This news release includes partial results from the DECISION trial. The partial results contained herein should be considered within the context of the full DECISION trial results, which are expected to be presented at an upcoming medical meeting.
See all RSS Newsfeeds


text:
High Rise Hotel Planned for Newport City
NEWPORT CITY – For years, Newport had grand, beautiful hotels on its Main Street, as seen in the yellowed photos from the Richardson-Cartee photo collection that have been printed on paper placemats and distributed throughout the area. If Frank and Michelle Richardi, owners of Lago Tratoria, have their way, a hotel will once again grace Newport's downtown.The Richardis want to open a 20-room hotel and restaurant on top of their existing restaurant. The plan calls for renovating the second floor and adding two additional floors to the business, which is located at the corner of Main and Coventry streets. The hotel will have a mixture of suites and rooms. The top floor will have French balconies that over look Lake Memphremagog."It's going to be an upscale, boutique hotel," said Frank Richardi. "It's also going to have a roof top bar and I'm going to introduce a new style of food to the area."Richardi is being tight lipped on what type of food he will serve at the new restaurant. However, he does promise that Lago Tratoria is here to stay."We're looking to fit in with the new downtown renaissance," he said. The hotel, once opened, will be close for guests to walk on Main Street and the boardwalk and will be a short driving distance to the Newport State Airport. "It's really part of what is happening here on Main Street."The hotel will be a private venture and will not be part of any chain. However, Richardi might be looking for a local investor. The target customer is the tourist market. He feels the hotel fits into expansions that are taking place in the region. The hotel means about a dozen new jobs for the area.Richardi hopes to start the project next spring and be finished within a year.


text:
State legislators, after a series of emotional hearings on the Newtown shootings, will pivot this week to a new challenge: closing projected budget deficits of nearly $2 billion over the next two years.
On Wednesday, Gov. Dannel P. Malloy will unveil his budget, resetting the table at the state Capitol and establishing the broad framework for the rest of the legislative session that is scheduled to end June 5. Although no governor gets everything requested, the proposal traditionally establishes the broad parameters of what is possible for the session.


text:
Developed to replace traditional filter bags and cages, United Air Specialists' new pleated bag filters feature a one-piece construction design that allows them to be used in new systems or as a simple retrofit in existing bag house equipment for improved system performance. Benefits of the pleated bag filters include: ProPulse expanded polytetrafluoruethylene (ePTFE) surface-loading technology with strong resistance to moisture and good release characteristics; increased filtration media efficiency for improved air quality and reduced dust emissions; 2-3 times filtration media surface area per filter for longer filter life; shorter more compact filters that reduce inlet abrasion and provide larger drop out area under filters; easy installation due to compact size and one-piece filter construction; lower initial and operating pressure drop for decreased systems operational cost. Available in a variety of configurations for top-load, bottom-load, and oval styles with multiple filter media options including ePTFE and spunbond polyester. High temperature media and configurations also available.
United Air Specialists Inc., Cincinnati, OH 888-515-8800 www.uasinc.com
For related equipment reviews, articles, and news, visit our Dust Collection & Air Pollution Control Equipment ZoneUnited Air Specialists Inc. | CLARCOR Industrial Air


text:
Transform your photos into one-of-a-kind, hand painted masterpieces!
Lilies by Theodora Dimitrijevic - 10" x 8"
Archival Matte Paper
Rolled in a Tube
Assembly Charge
Lilies poster by Theodora Dimitrijevic. Our posters are produced on acid-free papers using archival inks to guarantee that they last a lifetime without fading or loss of color. All posters include a 1" white border around the image to allow for future framing and matting, if desired.
Ships Within
2 - 3 business days
Ships From
Atlanta, GA
There are no comments for Lilies. Click here to post the first comment.
All prints ship in durable cardboard tubes.
Fine Art America is one of the largest, most-respected giclee printing companies in the world with over 40 years of experience producing museum-quality posters and prints. All of our posters are produced on state-of-the-art, professional-grade Epson printers.
We use acid-free paper with archival inks to guarantee that your posters last a lifetime without fading or loss of color. All posters include a 1" white border around the image to allow for future framing and matting, if desired.
Posters ship within 3 - 4 business days in durable cardboard tubes.
Average Rating (5 Stars):
Cam Niz
August 17th, 2018
I was born in Toronto, Canada in 1989. I started painting in watercolour in 1997 and began exhibiting in 2000. Since then, I've gone on to express my creativity in other mediums including acrylic, oil, drawing, photography, and computer generation. I love it when art is somewhat removed from the mainstream culture of what typically classifies it as a certain art form, such as a work that is gothic or fantasy inspired and is met halfway in both art genres. I love to travel, exercise, spend time with my friends.
Our return policy is very simple:
If you're not happy with a purchase that you made on FineArtAmerica.com, for any reason, you can return it to us within 30 days of the order date. As soon as it arrives, we'll issue a full refund for the entire purchase price. Please note - Fine Art America does not reimburse the outgoing or return shipping charges unless the return is due to a defect in quality.
Fine Art America sells thousands of pieces of artwork each month - all with a 100% money-back guarantee. We take great pride in the fact that hundreds of thousands of artists have chosen Fine Art America to fulfill their orders, and we look forward to helping you select your next piece!
Customer Service: 877-807-5901
(Call Any Time - 24 Hours Per Day)
All posters ship from our production facility within 2 - 3 business days of your order.


text:
Everton manager David Moyes was expected to be named the new manager of Manchester United yesterday, after Sir Alex Ferguson sent shockwaves through world soccer by announcing his retirement from the role.
Moyes, 50, met with Everton chairman Bill Kenwright in London on Wednesday, hours after Ferguson revealed he would be stepping down at Old Trafford after amassing 38 trophies in a glorious 26-year spell. The Everton manager, whose contract expires on June 30, was pictured on British television fleeing from journalists who had waited for him after the meeting and jumping into a waiting car.
Kenwright said the Scot would leave with the club's blessing.
"At the end of the day, David's contract is up in six weeks' time and he has a right to make his own decisions," Kenwright told Sky Sports News. "He has served this club wonderfully well."
Kenwright added that he thought Moyes would still be in charge for Everton's Premier League game with West Ham United on Sunday, which would be his last home game at the club.
In a fresh twist to the story, United issued a statement insisting that Wayne Rooney, the former Everton striker, still has a future at the club, after reports emerged that he had asked to leave.
Several British media outlets reported that Rooney had informed Ferguson of his desire to leave the club two weeks ago, but a United spokesman said: "Wayne Rooney is not for sale."
Rooney previously issued a transfer request in 2010, only to change his mind and sign a new five-year contract.
The England striker was handed his Everton debut by Moyes at the age of 16 in 2002 and joined United two years later in a £27 million (US$42 million) deal.
Moyes sued the player over derogatory comments about him in his 2006 autobiography, but the pair are since believed to have reconciled.
Wigan Athletic manager Roberto Martinez is reported to top Everton's candidates to succeed Moyes, but he said he was only focused on his side's meeting with Manchester City in tomorrow's FA Cup final.
"At this moment in time, it would be a waste of time [to think about the Everton job]," Martinez said. "The most important thing is to be as ready as we can on Saturday and then the two other finals we have in the league after that."
Moyes was reportedly identified by Ferguson as the man he wanted to succeed him, despite a lack of European experience and the fact he has failed to win a trophy during his 11-year Everton tenure.
Former United assistant coach Steve McClaren backed Moyes' expected appointment, telling the BBC: "He's a winner and has a work ethic similar to Sir Alex."
"He's also built a dynasty and legacy at Everton. He's waited many years for this opportunity and I hope he gets it," he said.
Real Madrid coach Jose Mourinho, the former Chelsea manager, had also been touted for the Old Trafford job, but Moyes was the odds-on favorite with all the leading British bookmakers.
Ferguson, 71, has guided United to 13 Premier League titles and two European Champions League crowns in a record-breaking spell at the club.
The British press hailed his achievements yesterday, with the Daily Telegraph writing: "History should remember him not just as Britain's finest football manager, but the best that the world has ever seen."
News of his retirement dominated the front and back pages of the national newspapers, with the Financial Times opining that he had given a "26-year masterclass in dealing with clashing personalities."


text: After a rough night out, it can be tempting to spend the first day of the new year sitting on the couch chugging coconut water and eating stale Santa cookies. But really, there's no better way to punch that New Year's Eve hangover straight in its guilty, haggard face than with a satisfying brunch. Plan to kick off 2013 right at one of these six must-try restaurants.


text:
Lots of Crazy Things Are Happening on Rihanna's Airplane Tour
Journalists are revolting against Rihanna shutting them out, and someone streaked.
In case you missed it, Rihanna is playing seven shows in seven cities in seven days to plug her new album Unapologetic (which we discuss here). She is traveling on a Boeing 777
with 777 with something like 150 journalists on board. And yeah, it's turning into a hellmouth in the sky a little bit. Julieanne Smolinski at Popdust writes that Rihanna's concerts are starting increasingly later than scheduled, setting the whole convoy behind, and that Rih-Rih is making herself completely scarce, enough so that "'where the hell is Rihanna?' has replaced any of her earwormy hooks." Maud Deitch and Mary H.K. Choi paint the madness in a back-and-forth post at MTV Style, with Choi writing, "The Australian with the harmonica is STREAKING ON THE PLANE as we scream 'save our jobs' and 'access' and 'interviews' and 'just one headline' at the abject lack of Rihanna time." As you could expect with all those rabid writers experiencing the ruckus in real time, there's lots more out there. And the tour still has two days left.


text:
In 2001 and 2002 Bombardier Transportation received an order from Porterbrook Leasing Company for the delivery of a total of 67 double-deck coaches intended for service on lines operated by the Danish State Railways. The contract covers the supply of ABs 7900 type double-deck driving cab coaches and both B 7700 and Bk 7800 type double-deck intermediate coaches. The coaches are designed for service speeds of up to 160 km/h and will provide a significant increase in carrying capacity. The special equipment onboard and the modern exterior and interior design of the vehicles are intended to make regional and suburban services even more attractive for travellers and operators alike. The coaches are air-conditioned and feature multipurpose areas with plenty of room for bicycles, strollers and wheelchairs. A closed toilet system and vending machines in a number of intermediate coaches emphasize the high level of comfort provided by the latest generation of double-deck coaches.
|27,270 mm (driving coach)
26,800 mm (intermediate coach)
|2,784 mm
|Max. Speed
|160 km/h
|Seated Passengers
|70 (driving coach)
121 (intermediate coach)
|140 (driving coach)
145 (intermediate coach)


text: Motorcycle safety technology has clearly entered a new phase of development with airbag systems being pursued by a variety of apparel manufacturers. The latest company to enhance it's riding suits with the technology is Alpinestars, purveyor of fine jackets, gloves, boots, etc. Alpinestars' airbag system, dubbed the Tech Air Race, the system easily integrates into what the company calls the Electronic Airbag Protection Suit. The two components combined create a leather racing suit that can calculate in eight milliseconds whether a rider is crashing, and if so, deploy a pair of airbags that protects the rider's body.


text:
Today Google debuted their second TV ad for the Nexus 7 and it follows a familiar story of a parent enjoying time with their child. The 60 second spot is about a curious little girl who enjoys a relaxing weekend with her mom.
Google is expected to ship around eight million Nexus 7 tablets this year, and it looks like they are spending enough on marketing to make that happen. Just yesterday Google placed an ad for the Nexus 7 directly on their home page.
Check out the clip below and let us know what you think. Do you enjoy Google's new direction in advertising?


text:
cpanfile-faq - cpanfile FAQ
Does cpanfile replace Makefile.PL or Build.PL?
No, it doesn't.
cpanfile is a simpler way to declare CPAN dependencies, mainly to your application rather than CPAN distributions.
In fact, most CPAN distributions do not need to switch to
cpanfile unless they absolutely want to take advantage of some of the features (see below). This is considered a new extension for applications and installers.
Why do we need yet another format?
Here are some of the reasons that motivates the new cpanfile format.
- Not everything is a CPAN distribution
First of all, it is annoying to write Makefile.PL when what you develop is not a CPAN distribution.
It gets more painful when you develop a web application that you want to deploy on a different environment using version control system (such as cloud infrastructure), because it requires you to often commit the META file or
inc/directory (or even worse, botu) to a repository when your build script uses non-core modules such as Module::Install or File::Copy::Recursive.
Many web application frameworks generate a boiler-plate
Makefile.PLfor dependency declaration and to let you install dependencies with
cpanm --installdeps ., but that doesn't always mean they are meant to be installed. Things can be often much simpler if you run the application from the checkout directory.
With cpanfile, dependencies can be installed either globally or locally using supported tools such as cpanm or carton. Because
cpanfilelists all the dependencies of your entire application and will be updated over time, it makes perfect sense to commit the file to a version control system, and push the file for a deployment.
- More control for the dependencies analysis
One of the limitation when I tried to implement a self-contained local::lib library path feature for cpanminus was that the configuration phase runs the build file as a separate perl process, i.e.
perl Makefile.PL.
This makes it so hard for the script to not accidentally load any modules installed in the local
site_perldirectory when determining the dynamic dependencies. With the recent evolution of CPAN installer ecosystem such as local::lib support, it makes things much easier if installers figure out whether dependencies are installed, instead of by build tools such as Module::Install.
- Familiar DSL syntax
This is a new file type, but the format and syntax isn't entirely new. The metadata it can declare is exactly a subset of "Prereqs" in CPAN Meta Spec.
The syntax borrows a lot from Module::Install. Module::Install is a great way to easily declare module metadata such as name, author and dependencies. cpanfile format is simply to extract the dependencies into a separate file, which means most of the developers are familiar with the syntax.
- Complete CPAN Meta Spec v2 support
cpanfilebasically allows you to declare CPAN::Meta::Spec prerequisite specification using an easy Perl DSL syntax. This makes it easy to declare per-phase dependencies and newer version 2 features such as conflicts and version ranges.
How can I start using
First of all, most distributions on CPAN are not required to update to this format.
If your application currently uses
Makefile.PL etc. for dependency declaration because of the current toolchain implementation (e.g.
cpanm --installdeps .), you can upgrade to
cpanfile while keeping the build file based installation working for the backward compatibility.
TBD: Support in other tools such as MakeMaker


text:
A doll
by Vulgar Clown August 26, 2003
A doll by another name, differing from a doll by being designed for tough, aggressive, "masculine" situations. Used by males to disguise their insecurity with being associated with traditionally "feminine" things. Just like a kilt is not caled a "skirt".
"Action figure"? What does that mean anyway? Is it an active thing? What does it mean? Call it what you like it, but any way that you look at it, an "action figure" is a doll by another name; "That which we call a rose/By any other word would smell as sweet."-Juliet, Romeo and Juliet
by Lorelili November 11, 2006
A plastic figure that usually does an action (hence the name). Are usually owned by 10 year old boys who incest that they're NOT or HAVE anything in common with a doll and 40 year old virgin nerds with a capital N who collect them along with dolls and not allow any part of it to leave the case until it becomes of ulimate value.
Timmy Turner: For now on I sticking with Action Figures...... which are completely different from dolls
by Da Master K May 20, 2006
by Joshua Tapp January 16, 2004
NOT a doll. Dolls are for girls. Action figures are much more masculine and cool. Often depicting certain super-heroes or video game/movie characters, and sometimes real people.
"Hey, man what are you doing playing with that batman doll?"
"Hey! This is an ACTION FIGURE! Not a doll.... Dolls are for girls..."
"Hey! This is an ACTION FIGURE! Not a doll.... Dolls are for girls..."
by commodore cool December 16, 2008
the adult synonym for the word "toy"; as done with confidence, and without humiliation.
and little Debo said to his mom, "its not a TOY, its an ACTION FIGURE! Get it right mom!"
by thesilentrebel January 16, 2012
With my husband out of town and the kids gone, last night I had to break out my action figure.
by cainmenace August 22, 2016


text:
The best digital experience is a consistent one.
Simplify the creation, management, and deployment of your content and assets across sites, mobile apps, and more.
Manage your sites with ease.
Quickly create and deliver relevant web and mobile experiences, easing the demands on IT.
Mobile content management
As you integrate mobile into your marketing efforts, ensure that the experience is ideal on every device.
Deliver immersive, personalized shopping experiences that incorporate video, social, and other dynamic media.
Managed Services
Streamline content deployment using Adobe as your single partner for hosting and support.
Marketing campaign management
Organize, launch, and optimize campaigns across digital channels from one place.
Multisite management
Manage multiple web and mobile sites centrally, and automate translation workflows.
Build communities that feel like home.
Connect with your customers through thriving online community experiences. Include forums, user groups, learning resources, and other social features that are valuable to your customers and employees.
Create engaging forms and documents.
Simplify enrollment, onboarding, and correspondence with forms and documents that easily integrate into web and mobile experiences.
Business-friendly authoring
Create forms faster than ever with easy drag-and-drop authoring with options for complex input types, assigning rules, and more.
Simplified form filling
Allow users to complete dynamic and responsive forms quickly using prefilled fields, help text, field validation, and e-signatures.
Efficient processing
Merge form and document data with existing systems, and develop automated workflows.
Personalized responses
Create personalized, interactive documents and statements that customers can access from anywhere.
Proactive security and tracking
Secure sensitive documents and control and track their use.
Continual improvement
Measure form and document experiences using Adobe Analytics, and improve them usingAdobe Target.
All of your assets in one place.
Easily manage images, videos, and other assets across every digital channel to deliver better customer experiences.
Dynamic media
Work with a single set of master assets and serve unlimited variations, including size, color, format, resolution, and crop.
Create, manage, and deliver interactive video. Make it available to all screens and devices with a single URL.
Personalized media
Test and preview content variations on your sites to deliver experiences tailored to individual customers. Help customers personalize product options before they buy.
Advanced search and metadata
Automatically assign metadata to assets, and instantly create shareable assets based on search attributes.
Project and workflow management
Plan, review, and approve the production of marketing assets using project templates and simple workflow tools.
Managed Services offerings
Store your assets in the cloud with Adobe as your single partner for hosting, security, and support.
The web is your asset.
Billions of pieces of social content are created every day. Livefyre lets you tap into that source to release a constant flow of fresh and authentic content — created by the people who care about what you do.
Learn how to solve business problems.
Read our use cases for best practices in Experience Manager.


text: Multimedia Login | Register Submit LinkLatest LinksTop HitsContactRss C-N.US | Current News Directory / Computers and Internet / Multimedia Alexa Ranking Pagerank Site Spotlight PR7 Web Directory Latest Featured Links Capital A List Feb 17, 2016 | Events PR: 1 Capital A List provides the ultimate resource for those keen to be involved in the biggest and most exclusive parties in the city. The company offers exclusive VIP membership to club guest lists in ... Read more Latest News - Slavebrain Jan 24, 2016 | Breaking News N/A Slavebrain collates all the news stories from around the world and categorizes them. All the stories are the ranked based on various metrics, allowing you to keep up with the breaking news and live ... Read more 3D Power Visualization Dec 11, 2015 | Architects PR: 1 3D Power is an architectural Visualization Studio, expert in 3D Photorealistic Rendering, 3D Architectural Walkthrough & 3D Interior Designing. Our Services: - Architectural 3D Rendering - ... Read more Diamond Drilling Company UK Nov 25, 2015 | Tools and Equipment N/A React Diamond Drilling Ltd are a UK company offering drilling, cutting and demolition services. ... Read more Natural Burlap Fabric May 27, 2015 | Textiles N/A naturalburlapfabric.com has unique clientele ranging from households, businesses and manufacturers dedicated to buy burlap fabric. With many years of experience upon our shoulders, we guarantee ... Read more My Account Username Register Friend List Free PR8 Directory Free Web Hosting Free Directory List Free List of Directories Niche Directory List General Directory List Free Directory List Latest News The island where cars are banned This building could save lives Clinton, Sanders in a dead heat Can Serena's conqueror build on shock triumph? Putin: 'Most polite President' shirt sparks fury This park is the length of a country What does the color of your pee mean? 9,100 evicted to make way for telescope Apple opposes hacking of killer's iPhone Obama: Americans are 'too sensible' to elect Trump Multimedia Digital Video Graphics Internet Broadcasting MPEG Music and Audio Online Entertainment Virtual Reality Powered By: © 2016 C-N,US. All rights reserved


text:
By Guest Author Linnea Schmidt
By Guest Author Ethan Guthman
By Guest Author Emily Larson
By Guest Author Katie Arnolds
Por Autor Invitado Katie Arnolds
By Guest Author Tanya L. Brown
By Christy Beitzel
Por Christy Beitzel
By Kelsey Repine
Por Kelsey Repine
By Guest Author Jacki Essig
By Guest Author, Saskia Bunge Montes
Por Autor Invitado, Saskia Bunge Montes
By Guest Author, Merlin Ariefdjohan
Por Autor Invitado, Merlin Ariefdjohan
By guest author Molly Terhune
Por Molly Terhune
By Guest Author John Soltys
Por Autor Invitado John Soltys
By Nicole L. Garneau, PhD
Por Autor Invitado, Kelsey Repine
By Guest Author, Kelsey Repine
By Guest Author, Molly Terhune
Por Autor Invitado, Molly Terhune
Guest Author, Lyndsay Krisher
Autor Invitado, Lyndsay Krisher
Guest Author, Katie Arnolds
Autor Invitado, Katie Arnolds
Guest Author, Merlin Ariefdjohan
Autor Invitado, Merlín Ariefdjohan
Guest Author, Katie Arnolds
Autor Invitado, Katie Arnolds
Guest Author, Veronica Searles Quick
Autor Invitado, Veronica Searles Quick
Autor Invitado, Merlín Ariefdjohan
Guest Author, Dr. Jessica Metcalf
Guest Author, Michael A. Bagley
By Chelsea Corser-Jensen
Conversations in Local Health Research
By Brian J. Kempf, PhD
By Rhea May, PhD
By Daniel Raible
By Katherine Lee, PhD
By Audrey Bergouignan, PhD
Thanks to ASMcue for the invitation to speak this year and to all the great educators and scientists in attendance!
By Katherine Brandao, PhD
Congrats to Bruce Randolph School for winning the [email protected] competition sponsored by LiveWell Colorado!
By Jennifer Marie Stratford, PhD
Member Response, Lactose Intolerance
A special thanks to the many readers who sent in comments and questions about "Today's Paleo Diet" recently published in Catalyst.
By Laura Harmacek
By Alexa Dickson, PhD
Guest Blog Post, Dr. Ernesto Salcedo
By Nicole L. Garneau PhD and Tanya Breeling
By Nicole Garneau, PhD
By Nicole L Garneau, PhD
How to Give Veggies a Competitive Edge with Kids By Melissa Wdowik, PhD, RD
By Ernesto Salcedo, PhD
By Keely Sudhoff, PhD
By Yo Pearl the Science Girl
By Devin Walecka
BY Devin Walecka
Message from the Health Sciences Team
By Bridget Coughlin, PhD
By Meghan Sloan, MA
By Jonathan Grudis, MA
Invite from the Health Sciences Team
10:30 to 11:30 a.m., Ricketson Auditorium
Brown Bag Lunch with speaker to follow presentation
Despite nearly sixty years of basic research and nearly 30 years of eradication efforts, poliovirus is still a public health problem. Poliovirus is still circulating in Nigeria, Pakistan, and Afghanistan with hundreds of cases annually with new outbreaks occurring annually in neighboring countries. The current eradication campaign faces scientific, financial, and social difficulties. Current research to understand how the virus functions could finally help eradicate this crippling disease. Join us for a presentation to learn more about how advances in virus genetics are helping local researchers at the University of Colorado develop a better polio vaccine.
Brian J. Kempf, PhD is a Research Associate for David J. Barton, PhD at the University of Colorado School of Medicine, Department of Microbiology.


text:
|MLB Career Stats
|23rd in NL
|19th in AL
|13th in NL
|4th in NL
|13th in NL
|17th in NL
|10th in AL
|23rd in NL
|4th in AL
|9th in NL
|9th in NL
|12th in NL
|11th in NL
|23rd in NL
|21st in AL
|10th in NL
|10th in AL
|24th in AL
|16th in NL
|May 3, 2010
|Seattle Mariners released LF Eric Byrnes.
|January 29, 2010
|Seattle Mariners signed free agent LF Eric Byrnes.
|January 15, 2010
|Arizona Diamondbacks designated Eric Byrnes for assignment.
|September 5, 2009
|Arizona Diamondbacks activated LF Eric Byrnes from the 15-day disabled list.
|August 16, 2009
|sent LF Eric Byrnes on a rehab assignment to Reno Aces.
|June 26, 2009
|Arizona Diamondbacks placed LF Eric Byrnes on the 15-day disabled list. Fractured left hand
Hit home runs in back-to-back games on 3 occasions (May 8 & 9 vs. Philadelphia, July 26 & 27 vs. Florida & Atlanta, and Sept. 3 & 4 vs. San Diego)...Had a 12-game hit streak from May 5-18, batting .348 (16-for-46) with 2 doubles, 1 triple, 3 home runs and 6 RBI...Hit 2 solo home runs on May 30 at Philadelphia, his fifth career game with 2 home runs...Was 4-for-5 with a double, a home run and 3 RBI on June 20 against Tampa Bay, the fifth 4-hit game of his career...Hit safely in 18 of 19 games from June 15-July 4 (.329, 27-for-82), including two 9-game hit streaks...Led off game with a home run 3 times, something he has now done 7 times in his career...Entered the All-Star break with 110 hits, the highest first half total of his career and tied for fifth in the National League...Strung together an 8-game hit streak from July 20-27, batting .323 (10-for-31) with 2 home runs and 8 RBI, including home runs on consecutive days (July 26 & 27 vs. Florida and Atlanta)...The home run on July 27 was a 3-run walk-off home run in the ninth inning, the second of his career, and the first in a string of 3 consecutive walk-off victories for the D-backs...Recorded a .987 fielding percentage, committing a career-high 5 errors over a career-high 1390.0 innings...spent the majority of the season patrolling left field (970.0 innings)...Ranked fourth in the National League with 12 outfield assists...Did not appear as a pinch hitter all season for the first time in his career.2006 After struggling in 2005 while playing for three different teams, Byrnes set several career highs with the D-Backs in 2006, including home runs (26), RBIs (79) and stolen bases (25). He hit .267 on the season and is expected to be the starting left fielder in 2007. 2005 Rockies were the 2nd of 3 teams for Byrnes in '05, as he played just 15 games in a Colorado uniform before he was dealt again...the 29-year-old outfielder had been with Oakland his entire professional career before he was acquired by Colorado on the day after the All-Star Game...joined the Rox after batting .266 with 7 home runs and 24 RBI in 59 games for the Athletics in the first half...batted .189 (10-for-53) with 2 doubles and 5 RBI in 15 games with the Rockies...started 14 of final 15 games with Colorado...went 5-for-17 (.294) with a double and 3 RBI in first 4 NL games, but hit just .139 (5-for-36) with a double and 2 RBI in final 11 contests before he was traded to Baltimore...hit .192 with 3 home runs and 11 RBI in 52 games for the O's...for the year, batted .226 with 10 home runs and 40 RBI in 126 total games for Oakland, Colorado and Baltimore. 2004 Had the best season of his career as he hit .283 with 20 home runs and 73 RBI, all career highs...also posted career bests in games (143), at bats (569), runs (91), hits (161), doubles (39), walks (46), stolen bases (17), on-base percentage (.347) and slugging (.467)...his 20 home runs were two more than his career total of 18 entering the season, marking the second consecutive season he has hit more home runs than his career total entering the season...his career high batting average was aided by a .344 (54 for 157) mark against left handed pitching, the third best mark against southpaws in the American League...it was the fourth best mark by an Athletic since 1974 (minimum 150 plate appearances)...hit seven of his 20 home runs against left handed pitching and 16 of his 38 career home runs have come against southpaws...has a .306 (116 for 379) career average against left-handers and .253 (189 for 746) against right-handers...was successful in 17 of his 18 (94.4%) stolen bases attempts and is now 33 for 37 (89.2%) in his career...since 1996, only two Athletics have stolen more bases in a season than his 17 in 2004 (Rickey Henderson, 66 in 1998; Johnny Damon, 27 in 2001)...led the A's in stolen bases, runs, doubles and hit by pitches (12)...his 91 runs scored were the fewest by an A's team leader since Jason Giambi had 66 in 1997...the hit by pitches tied for 10th in the AL and tied for the seventh best single season total in Oakland history...had 11 assists which tied for fourth among AL outfielders...tied with Mark Kotsay for the team lead in outfield assists and they had the most assists by an A's outfielder since Matt Stairs had 13 in 1999...made a total of 137 starts for the A's, all in the outfield... spent most of the season as the A's left fielder where he made 98 starts, but he also made 22 starts in center field and 17 in right field...made 60 starts hitting second and 38 batting first...hit .307 (51 for 166) with seven home runs as the A's leadoff hitter...led off the game with a home run on June 6 against Toronto and June 12 against Pittsburgh...now has four career leadoff home runs which ties Tony Phillips for third most in Oakland history behind Rickey Henderson (43) and Bert Campaneris (10)...nine of his home runs either tied the game or put the A's ahead as did 27 of his 73 RBI...got off to a strong start for the second consecutive season as he batted .327 (17 for 52) in April and .281 (27 for 96) in May...now has a .313 (101 for 323) career average in the first two months of the season...hit his first career "walk-off" home run on May 7 against Minnesota, a two-run shot in the bottom of the 13th inning off Terry Mulholland in the A's 11-9 win...had his first of three twohomer games on June 12 against Pittsburgh, the first three multi-homer games of his career...had back-to-back three hit games on June 12 and 13 against the Pirates which put his batting average at .308...then went 22 for 110 (.200) over a 30- game stretch from June 15 to July 22 which dropped his season average to .269...had a career long 0 for 18 streak from June 23 to 29...had his second career two-homer game on July 4 at San Francisco and went 3 for 4 in that game with a career high six RBI...had six home runs and 21 RBI over a 12-game stretch from July 23 to August 4 and batted .429 (18 for 42) over that span...that included his third career two-homer game on July 30 at Texas...was named AL Player of the Week for the week of July 26 to August 1 after going 11 for 25 (.440) with seven runs, two doubles, three home runs and nine RBI...it was his first career Player of the Week award...drove in at least one run in six consecutive games from July 23 to 28 (12 total)...finished July with eight home runs and 24 RBI in 24 games...the home runs and RBI were his most ever in a month...was successful in each of his first 10 stolen base attempts and had 11 consecutive stolen bases dating back to 2003 when he was caught stealing third base by Ivan Rodriguez on August 10...had a season best 12-game hitting streak from August 6 to 17 (16 for 56, .286)...hit .311 (37 for 119) in August, his second of two months over .300...batted .333 (13 for 39) against Boston and now has a .364 (20 for 55) career average against the Red Sox, his best against any AL team...had four home runs and 12 RBI against Texas and now has eight home runs and 22 RBI in his career against the Rangers, both his best figures against any team. 2003 Replaced the injured Jermaine Dye on April 24 and for the next nine weeks of the season, he was one of the hottest players in baseball...beginning on April 24, he hit .352 (83 for 236) with 11 home runs and 41 RBI over a 59-game stretch that culminated on June 29 when he hit for the cycle at San Francisco...then went 9 for 95 (.095) over his next 28 games through August 14 and finished the year at .263...had career highs in every offensive category, including a team leading nine triples...the triples tied for the third best total in Oakland history and were the most by an Athletic since Luis Polonia had 10 in 1987...ranked tied for fourth in the American League in triples...tied for the team lead with 10 stolen bases...had 12 home runs and 51 RBI in 121 games after entering the season with six home runs and 16 RBI in 119 career games...batted .380 (49 for 129) as a left fielder and .216 (60 for 278) as a center fielder...made 77 starts in center field and 31 in left field and also appeared in two games in right field...hit .270 (61 for 226) in the leadoff spot and made 54 starts batting first which was second on the club to Mark Ellis...made 67 consecutive starts from April 25 to July 9, including 48 consecutive starts in the leadoff spot from May 17 to July 9...made the A's opening day roster after batting .360 with five home runs and 13 RBI in 24 spring training games...tied for fifth in the Cactus League in home runs and led the A's in RBI...appeared in nine of the A's first 17 games, making five starts...replaced Dye in the fifth inning on April 24 against Detroit after he tore cartilage in his right knee fielding a Dean Palmer double...had his first multiple hit game of the season that day and moved into the starting line-up on April 25...had seven consecutive games with an extra base hit from May 8 to 15 (four doubles, three triples, one homer)...that began a career-high 22 game hitting streak from May 8 to June 1, during which he hit .376 (32 for 85) with 10 doubles, three triples, four home runs and 20 RBI...it was the fourth longest hitting streak in Oakland history and the third longest hitting streak in the A.L. in 2003...went 0 for 9 in his next two games before putting together a 10-game hitting streak from June 5 to 15 (15 for 40, .375)...had the hitting streak snapped on June 17 and then put together a 13-game hitting streak from June 18 to 30 (21 for 59, .356)...had a career high four RBI on May 15 at Detroit...homered in all three games of the Montreal series, June 13-15, the first time he had homered in three straight games in his career...tied an Oakland record with a career high five hits on June 29 at San Francisco when he hit for the cycle...singled in the first, doubled in the second, homered in the fifth, doubled again in the seventh and then completed the cycle with a two-out triple in the ninth inning...it was the 16th cycle in Athletics history, the fifth since the franchise moved to Oakland...it was the first cycle by an A's outfielder since Elmer Valo at Chicago on August 2, 1950...ended up batting .500 (13 for 26) in six games against the Giants, his best average against any team in 2003...hit .373 (28 for 75) with four home runs and 18 runs scored in interleague play, all of which were the best figures on the A's...batted .356 in May and .322 in June with 26 runs scored, the third most runs in the A.L. in the month and the most runs scored in one month by an Athletic since Jason Giambi had 26 in September, 2000...at the end of June, he had hit safely in 23 of his last 24 games and 45 of his last 48 and was batting .335 overall...that was the fifth best average in the A.L., his highest ranking of the season...then hit .095 (7 for 74) in 20 games in July...since 1974, that was the lowest one-month batting average by an Oakland player with a minimum of 75 plate appearances...previous low was .129 by Don Baylor in April of 1976...he became just the fourth major leaguer since 1974 to hit under .100 in a month with a minimum of 75 plate appearances...joins Don Baylor (.062 in April, 1981 with California), Royce Clayton (.083 in May, 2003 with Milwaukee) and Greg Vaughn (.099 in April, 2002 with Tampa Bay)...snapped a career long 0 for 17 slump on July 20...appeared in just 12 of the A's 28 game from July 22 to August 20 before ending his 9 for 95 slump with a two-hit game at Boston on August 21...the slump had dropped his average 66 points to .270 but he went 7 for 17 (.412) over a nine-game stretch from August 21 to September 8...replaced the injured Chris Singleton in center field on September 9 and started 16 of the A's final 18 games (8 for 49, .163)...snapped a 39-game, 121-at bat homerless streak on September 11 against Anaheim...the A's won that game and were 9-3 in games in which homered in 2003...are 14-4 (.778) when he homers in his career...the home run was a two-run shot and seven of his 12 home runs came with men on base (three two-run, four three-run). 2002 Began the season at Triple-A Sacramento but was recalled to Oakland on May 8 and spent the remainder of the season with the A's...most of his playing time came as a late inning defensive replacement or as a pinch runner...appeared in 90 games but had just 94 at bats...pinch ran 27 times and had 45 games where he did not bat...appeared in 52 games in left field, 22 in right field and 10 in center field...made 19 starts (10 in left, six in right and three in center) and was 17 for 66 (.258) in those games...made just eight starts after the All-Star Break and just three over the final 40 games...batted .245 for the season but fared better in Oakland where he hit .351 (13 for 37) with two of his three home runs compared to .175 (10 for 57) on the road...was 2 for 11 (.182) with five strikeouts as a pinch hitter but is 5 for 17 (.294) in his career in the pinch...had a two-run triple in his 2002 A's debut on May 8 against Boston, matching his career high for RBI...then had his first career three-hit game in a start in left field on May 16 against the Red Sox at Fenway Park...both of his triples in 2002 came against Boston and he was 5 for 7 (.714) in four games against the Red Sox...started four of the A's seven games from May 11 to 18 and was 4 for 16 (.250)...hit his first home run of the season on June 6 against Seattle in a start in right field...second home run came in the final game before the All-Star Break on July 7 against Kansas City in a start in left field...matched his career high with two RBI in that game...had just three RBI after the break...including a career high tying two on September 28 at Texas when he also hit his third home run of the season and scored three times...appeared in two Division Series games against Minnesota and batted once...struck out as a pinch hitter to end Game 4...hit .261 with four home runs, 16 RBI and five stolen bases in 31 games at Sacramento...his average broke down to .389 (7 for 18) against left handed pitching and .238 (24 for 101) with all four of his home runs against right handers...batted .389 (7 for 18) with runners in scoring position and two outs...appeared in 17 games in left field and 13 in center field...hit .174 (8 for 46) over his first 12 games and .315 (23 for 73) over his final 19...played for Licey in the Dominican Republic and batted .244 (22 for 90) with five home runs and 13 RBI in 23 games.Career:


text:
You have selected the item below to be added to your Shopping Basket.
Enter the quantity you wish to sell then click
Add to Basket...
U.S. Silver Dollars Minted Prior to 1936 - Roll of 20 Coins
If you have any questions please resolve them with
Goldmasters Precious Metals before placing your request to sell!
*** Total:$0.00***


text:
Job Search / Re: below-curve hls 2L re: oci prospects« on: June 23, 2008, 11:41:21 PM »
I know people with B/B- averages who didn't have trouble getting a job in NY last time around (albeit not at the V20).
What firms did they get offers from? Please share... PM me if you'd like.


text:
Control.Validated Event
The .NET API Reference documentation has a new home. Visit the .NET API Browser on docs.microsoft.com to see the new experience.
Occurs when the control is finished validating.
Assembly: System.Windows.Forms (in System.Windows.Forms.dll)
When you change the focus by using the keyboard (TAB, SHIFT+TAB, and so on), by calling the Select or SelectNextControl methods, or by setting the ContainerControl.ActiveControl property to the current form, focus events occur in the following order:
When you change the focus by using the mouse or by calling the Focus method, focus events occur in the following order:
If the CausesValidation property is set to false, the Validating and Validated events are suppressed.
If the Cancel property of the CancelEventArgs is set to true in the Validating event delegate, all events that would usually occur after the Validating event are suppressed.
Do not attempt to set focus from within the Enter, GotFocus, Leave, LostFocus, Validating, or Validated event handlers. Doing so can cause your application or the operating system to stop responding. For more information, see theWM_KILLFOCUStopic, and the "Message Deadlocks" section of the About Messages and Message Queues topic.
For more information about handling events, see Handling and Raising Events.
The following code example uses the derived class TextBox and validates an e-mail address that the user enters. If the e-mail address is not in the standard format (containing "@" and "."), the validation fails, an ErrorProvider icon is displayed, and the event is canceled. This example requires that a TextBox and ErrorProvider control have been created on a form.
private void textBox1_Validating(object sender, System.ComponentModel.CancelEventArgs e) { string errorMsg; if(!ValidEmailAddress(textBox1.Text, out errorMsg)) { // Cancel the event and select the text to be corrected by the user. e.Cancel = true; textBox1.Select(0, textBox1.Text.Length); // Set the ErrorProvider error with the text to display. this.errorProvider1.SetError(textBox1, errorMsg); } } private void textBox1_Validated(object sender, System.EventArgs e) { // If all conditions have been met, clear the ErrorProvider of errors. errorProvider1.SetError(textBox1, ""); } public bool ValidEmailAddress(string emailAddress, out string errorMessage) { // Confirm that the e-mail address string is not empty. if(emailAddress.Length == 0) { errorMessage = "e-mail address is required."; return false; } // Confirm that there is an "@" and a "." in the e-mail address, and in the correct order. if(emailAddress.IndexOf("@") > -1) { if(emailAddress.IndexOf(".", emailAddress.IndexOf("@") ) > emailAddress.IndexOf("@") ) { errorMessage = ""; return true; } } errorMessage = "e-mail address must be valid e-mail address format.\n" + "For example 'firstname.lastname@example.com' "; return false; }
Available since 1.1


text:
TIGERVILLE, S.C. - King College split a Saturday softball doubleheader at North Greenville (S.C.) University with a 12-3 Lady Tornado win in game two after North Greenville took the opener 3-1.
The split moved King to 10-24 while North Greenville ended the day at 13-16.
In the second contest King exploded for a dozen runs which tied the team high in a contest of 2011. The Lady Tornado scored three times in the first, two more in the third with a fifth-inning score before six in the sixth. The six-run inning outscored the output from 26 games earlier in the season. The 12 runs helped boost King's scoring average up from 3.0 runs per game up to 3.3.
Tiffany Brand (Knoxville, Tenn.) went 3-for-4 while Stephanie Mueller (Mt. Washington, Ky.) was 2-for-3 with a home run and four RBIs. Tiffany Harris (Tazewell, Va.) also drove in three runs while Cassie Ringstaff (Richlands, Va.) and Lauren Wilson (Abingdon, Va.) scored three times apiece.
Rachael Wilmoth (Morristown, Tenn.) completed six innings with three runs on the same number of hits for her fifth win of 2011.
In game one King tied things with bases loaded walk issued to Shauna Haga (Blountville, Tenn.) in the fourth. Pinch runner Natasha Dean (Church Hill, Tenn.) was on third for Kendall Brabson (Bean Station, Tenn.) who singled to start the frame.
Samantha Watts (Nashville, Tenn.) tossed six innings with five hits which led to three runs, two earned. She struck out five with only one walk.
North Greenville's Laura Hopper had two of the squad's five hits with a run scored.
The home team answered King's fourth inning run with the go ahead and an insurance score in the bottom half of the inning.
Taylor Roof went all seven innings with one run on four hits and eight strikeouts.
King welcomes Carson-Newman (Tenn.) College for a 2 p.m. doubleheader Tuesday. When the two played in Jefferson City on Feb. 23 Carson Newman won both games, 9-0 and 9-1.


text:
We know that plucking the eyebrows is forbidden in sharee'ah, and all the scholars are unanimously agreed on that. But every day we see on the religious satellite channels female presenters and daa'iyahs who are adorned, with plucked eyebrows, claiming that this is not haraam. What is your ruling on that?.
It is not permissible for a woman to uncover any part of her body in front of non-mahram men. That includes the face and hands, as has been explained in the answer to question no. 11774.
The prohibition is stricter if she has applied cosmetics and adornments so that she can be seen by men in that state. For more information please see the answer to question no. 111839.
With regard to plucking the eyebrows, it is proven that the Prophet (peace and blessings of Allaah be upon him) cursed the one who does that, which indicates that it is a major sin.
See the answer to question no. 2162.
After the ruling becomes clear from the words of the Prophet (peace and blessings of Allaah be upon him), who did not speak on the basis of his own whims and desires, rather it was revelation that was revealed to him, what the Muslim must do is follow him, and avoid that which angers Allaah and brings down His curse upon a person. Each person is accountable for himself.
As for these broadcasters and others, we ask Allaah to guide them to the right path, and to make them a good example for other women.
For more information please see the answer to question no. 21393.
And Allaah knows best.